Associations - ARID1A mutation

ARID1A mutation ARID1A mutation	Non Small Cell Lung Cancer NSCLC	ARID1A mutation ARID1A mutation	Non Small Cell Lung Cancer NSCLC	durvalumab + CP-675206 Sensitive: B - Late Trials	durvalumab + CP-675206 Sensitive: B - Late Trials
ARID1A mutation ARID1A mutation	Non Small Cell Lung Cancer NSCLC	ARID1A mutation ARID1A mutation	Non Small Cell Lung Cancer NSCLC	Immunotherapy Sensitive: B - Late Trials	Immunotherapy Sensitive: B - Late Trials
ARID1A mutation ARID1A mutation	Renal Cell Carcinoma RCC	ARID1A mutation ARID1A mutation	Renal Cell Carcinoma RCC	sunitinib Sensitive: B - Late Trials	sunitinib Sensitive: B - Late Trials
ARID1A mutation ARID1A mutation	Hepatocellular Cancer HCC	ARID1A mutation ARID1A mutation	Hepatocellular Cancer HCC	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Gastric Cancer Gastric Cancer	ARID1A mutation ARID1A mutation	Gastric Cancer Gastric Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	ARID1A mutation ARID1A mutation	Esophageal Adenocarcinoma Esophageal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Gastrointestinal Cancer Gastrointestinal Cancer	ARID1A mutation ARID1A mutation	Gastrointestinal Cancer Gastrointestinal Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Head and Neck Cancer Head and Neck Cancer	ARID1A mutation ARID1A mutation	Head and Neck Cancer Head and Neck Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Breast Cancer Breast Cancer	ARID1A mutation ARID1A mutation	Breast Cancer Breast Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Endometrial Cancer Endometrial Cancer	ARID1A mutation ARID1A mutation	Endometrial Cancer Endometrial Cancer	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	ARID1A mutation ARID1A mutation	Pancreatic Ductal Adenocarcinoma Pancreatic Ductal Adenocarcinoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Melanoma Melanoma	ARID1A mutation ARID1A mutation	Melanoma Melanoma	Immunotherapy Sensitive: C3 – Early Trials	Immunotherapy Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Neuroendocrine Tumor Neuroendocrine Tumor	ARID1A mutation ARID1A mutation	Neuroendocrine Tumor Neuroendocrine Tumor	toripalimab Sensitive: C3 – Early Trials	toripalimab Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Solid Tumor Solid Tumor	ARID1A mutation ARID1A mutation	Solid Tumor Solid Tumor	AZD6738 Sensitive: C3 – Early Trials	AZD6738 Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Cervical Cancer Cervical Cancer	ARID1A mutation ARID1A mutation	Cervical Cancer Cervical Cancer	bevacizumab + rucaparib Sensitive: C3 – Early Trials	bevacizumab + rucaparib Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Endometrial Cancer Endometrial Cancer	ARID1A mutation ARID1A mutation	Endometrial Cancer Endometrial Cancer	bevacizumab + rucaparib Sensitive: C3 – Early Trials	bevacizumab + rucaparib Sensitive: C3 – Early Trials
ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	ARID1A mutation ARID1A mutation	Cholangiocarcinoma Cholangiocarcinoma	sintilimab Sensitive: C4 – Case Studies	sintilimab Sensitive: C4 – Case Studies
ARID1A mutation ARID1A mutation	Colorectal Cancer CRC	ARID1A mutation ARID1A mutation	Colorectal Cancer CRC	cetuximab Resistant: D – Preclinical	cetuximab Resistant: D – Preclinical
ARID1A mutation ARID1A mutation	Ovarian Cancer Ovarian Cancer	ARID1A mutation ARID1A mutation	Ovarian Cancer Ovarian Cancer	GSK2816126 Sensitive: D – Preclinical	GSK2816126 Sensitive: D – Preclinical
ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	GSK2816126 Sensitive: D – Preclinical	GSK2816126 Sensitive: D – Preclinical
ARID1A mutation ARID1A mutation	Gastric Cancer Gastric Cancer	ARID1A mutation ARID1A mutation	Gastric Cancer Gastric Cancer	EZH2 inhibitor Sensitive: D – Preclinical	EZH2 inhibitor Sensitive: D – Preclinical
ARID1A mutation ARID1A mutation	Ovarian Cancer Ovarian Cancer	ARID1A mutation ARID1A mutation	Ovarian Cancer Ovarian Cancer	NXP900 Sensitive: D – Preclinical	NXP900 Sensitive: D – Preclinical
ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	ARID1A mutation ARID1A mutation	Bladder Cancer Bladder Cancer	OTX015 Sensitive: D – Preclinical	OTX015 Sensitive: D – Preclinical